| Date | Time | Source | Headline | Symbol | Company |
| 07/11/2024 | 12:21PM | iHub Newswire | FeaturedCannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing | | |
| 04/15/2009 | 5:11PM | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (DEFA14A) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/15/2009 | 5:11PM | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (DEFA14A) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/15/2009 | 3:03PM | Edgar (US Regulatory) | Additional Proxy Soliciting Materials - Non-Management (definitive) (DFAN14A) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/15/2009 | 3:02PM | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (SC 13D/A) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/15/2009 | 10:45AM | PR Newswire (US) | Letter From Carl Icahn to Amylin Pharmaceutical, Inc. | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/13/2009 | 8:01AM | Edgar (US Regulatory) | Proxy Soliciting Materials (revised) (PRER14A) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/10/2009 | 12:36PM | Dow Jones News | UPDATE:Amylin Co-Founder Resigns From Board Amid Proxy Fight | NASDAQ:AMLN | Amylin Pharmaceuticals Inc. |
| 04/10/2009 | 10:46AM | Dow Jones News | Amylin Co-Founder Resigns From Board Amid Proxy Fight | NASDAQ:AMLN | Amylin Pharmaceuticals Inc. |
| 04/09/2009 | 5:28PM | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (SC 13D/A) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/09/2009 | 5:02PM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/09/2009 | 5:01PM | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (DEFA14A) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/09/2009 | 4:15PM | PR Newswire (US) | Amylin Pharmaceuticals to Webcast First Quarter Results | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/06/2009 | 3:13PM | Dow Jones News | Amylin Tries To Distance Itself From Novo Nordisk Drug | NASDAQ:AMLN | Amylin Pharmaceuticals Inc. |
| 04/03/2009 | 4:09PM | Edgar (US Regulatory) | Additional Proxy Soliciting Materials - Non-Management (definitive) (DFAN14A) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/03/2009 | 4:09PM | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (SC 13D/A) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/03/2009 | 1:26PM | Business Wire | Eastbourne Capital Sends Letter to Amylin Pharmaceuticals Board of Directors | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/03/2009 | 1:14PM | Edgar (US Regulatory) | Proxy Statement - Contested Solicitations (preliminary) (PREC14A) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/03/2009 | 8:51AM | Dow Jones News | 2nd UPDATE: Novo Nordisk Shares Slump On Drug Launch Fears | NASDAQ:AMLN | Amylin Pharmaceuticals Inc. |
| 04/03/2009 | 6:02AM | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (DEFA14A) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/03/2009 | 6:02AM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 04/03/2009 | 5:05AM | Dow Jones News | UPDATE: Novo Nordisk Shares Slump On Liraglutide Launch Fears | NASDAQ:AMLN | Amylin Pharmaceuticals Inc. |
| 04/02/2009 | 8:41PM | PR Newswire (US) | Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/31/2009 | 4:05PM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/31/2009 | 3:54PM | Edgar (US Regulatory) | Additional Proxy Soliciting Materials - Non-Management (definitive) (DFAN14A) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/31/2009 | 11:35AM | Dow Jones News | UPDATE:FDA Sees Few Cardiovascular Events In Liraglutide Trials | NASDAQ:AMLN | Amylin Pharmaceuticals Inc. |
| 03/31/2009 | 8:02AM | Business Wire | Eastbourne Capital Comments on Amylin Pharmaceuticals Lawsuit in Delaware & Recent Developments in Effort to Enjoin Company | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/31/2009 | 8:00AM | PR Newswire (US) | Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/30/2009 | 4:07PM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 03/30/2009 | 4:06PM | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (DEFA14A) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |